Page 67«..1020..66676869..8090..»

Weekend humor from Celia Rivenbark: Oh, so NOW hormone replacement is ok NC Newsline – NC Newsline

Posted: May 27, 2024 at 2:49 am

Hey ladies! Remember a few years ago when they said we shouldnt take hormone replacement therapy for menopause symptoms like hot flashes and night sweats? They said it was bad for you! It could give you cancer! Use guided imagery to power through those sweats and headaches and mood swings! Better to be safe than sorry.

Fun fact: Turns out the science wasnt nearly as sciency as we thought and some of us couldve skipped a decade of severe to moderate crazy-making unpleasantness. Now, they say its perfectly OK, and may even be better for you to take sensible doses of estrogen. (For the three men still reading, estrogen is Latin for Lord, dont let me kill my husband fore the house is paid for.)

Not only is hormone replacement making a comeback but also it turns out its GOOD FOR YOU. Your heart just loves it! When properly dosed, modern cocktails of HRT can swaddle your heart in protective goodness AND protect against bone loss!

Mmmmkay.

Ima need to speak to someone right now. RIGHT FRIKKIN NOW. Wheres Cousin Eddy when you need him? Remember how he kidnapped Clark Griswolds miserly boss in Christmas Vacation and brought him to the Griswold home just so Clark could yell at him in person? Yeah, that would be kind of perfect. Get me the researcher who said reports of cancer and strokes were flawed. Ill wait.

Im righteously angry. The kind of angry that makes the oft-maligned Karen complaining about the degree of wilt in her Cobb salad seem downright quaint by comparison.

Whats next? Smoking is good for you? The tar and nicotine meet up inside your lungs and knit tiny sweater vests you can cough out and give as holiday gifts to your loved ones?

What about asbestos? Should I return to the 1950s-built house I grew up in and lick the exterior shingles because it will give me great eyesight and, interestingly, a useful third hand?

What about lead pipes and paint? Are those going to be OK, too? Will we learn that rather than causing learning disabilities and life-altering physical ailments lead is the secret ingredient in the Barefoot Contessas irresistible crispy-skinned roast chicken?

Speaking of food, remember how they told us not to eat eggs? And then they were OK. And then they werent. And then they wereIm not even sure anymore.

The new guidelines of HRT Okie Dokie (my term, not theirs) applies to women under 60. While Im happy for my sister-girls in their 50s, I hope they know theres a whole bunch of us who still have to apologize to a clerk at TJ Maxx who had the wretched misfortune to ask, again, if wed like to apply for a store credit card. There was NO reason to scream. Let alone scream Sure because apparently I look like I cant even afford the stuff in this GODFORSAKEN sea of sign art, gallon jars of pink Himalayan sea salt and garlic presses. So many, many garlic presses

Yes, we acted ugly because we had no estrogen. The stuff that had once plumped our skin, hydrated our parts and made us look at our spouses with more desire and less homicide.

To be sure, theyve done some important tweaking over the years to make HRT safer, like using patches instead of pills (greatly reduces risk of stroke) and keeping the recommendation to women under 60. (Apparently, the bad study had too many older women and yall know how we can be.)

Todays HRTs benefits outweigh the risks, they say. And thats great news for millions of women. Yay you. My generation toughed it out and now find ourselves on the other side, newly obsessed with digging in the dirt and subscribing to something called Britbox.

Just you wait.

Here is the original post:
Weekend humor from Celia Rivenbark: Oh, so NOW hormone replacement is ok NC Newsline - NC Newsline

Posted in Hormone Replacement Therapy | Comments Off on Weekend humor from Celia Rivenbark: Oh, so NOW hormone replacement is ok NC Newsline – NC Newsline

Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 – Industry Trends, Share … – GlobeNewswire

Posted: May 27, 2024 at 2:49 am

Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Hormone Replacement Therapy Market, Size, Forecast 2024-2032, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis" report has been added to ResearchAndMarkets.com's offering.

The global Hormone Replacement Therapy (HRT) market is experiencing significant growth, with an estimated value of US$ 20.91 Billion in 2023. A consistent compound annual growth rate (CAGR) of 6.18% is forecasted from 2024 to 2032, culminating in a market size of US$ 35.86 Billion by the end of the forecast period. This expansion is predominantly driven by an aging population, rising prevalence of menopausal symptoms, increased awareness, and advancements in hormone replacement products and therapies.

Women worldwide are increasingly experiencing menopausal symptoms and hormonal imbalances, compelling a growing need for effective HRT. The demand for HRT is bolstered by the projected worldwide population growth, indicating a substantial future market for hormone therapies. As reported by the NHSBSA Statistics and Data Science, England has seen a significant increase in prescribed HRT items, demonstrating the rising prominence of hormone replacement therapy in healthcare regimes.

Advancements and Trends

Continuous research and development, coupled with product approvals such as Ascendis Pharma A/S's SKYTROFA, are anticipated to further propel the hormone therapy market's growth. The increasing awareness of menopausal challenges in economies such as China and India is steadily translating into heightened market activity. Further, the surge in hormonal disorders is creating opportunities for market expansion, as effective treatments for symptoms like mood swings and reduced libido are sought after.

United States Market Analysis

The United States holds the leading position in the Hormone Replacement Therapy market, supported by an increase in therapy utilization among the target demographic and the continuous introduction of innovative drug delivery technologies. A significant portion of post-menopausal women in the US have utilized HRT, according to NIH. With a substantive patient population affected by conditions such as thyroid hormone imbalances, the market is set to maintain its robust growth trajectory.

Key Companies in the Market

The competitive landscape of the global Hormone Replacement Therapy market features key players including Abbott Laboratories, Bayer AG, Eli Lilly & Company, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Abbvie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd, and Dr. Reddys Laboratories Ltd. Recent developments such as FDA approvals and strategic partnerships accentuate these companies' commitment to meeting the growing demand for advanced HRT solutions.

Segments and Regional Insights

The global Hormone Replacement Therapy market encompasses various product types, disease types, routes of administration, and distribution channels. The market analysis includes segments like estrogen, human growth hormone, thyroid hormone, testosterone hormone, and progestogen replacement therapies. Additionally, the market explores different disease types and administrative routes along with distribution via hospital pharmacies, retail stores, and online pharmacies. The comprehensive market division also offers a granular view of HRT adoption patterns across a global spectrum covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The insights presented reflect the growing significance of Hormone Replacement Therapy and illustrate the market's future outlook in relation to demographic shifts, scientific advancements, and healthcare awareness. The global interest in achieving enhanced quality of life post-menopause and managing hormonal disorders underlines the importance of HRT, ensuring its relevance and expansion in the coming years.

Key Attributes:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/8cg2rs

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Visit link:
Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 - Industry Trends, Share ... - GlobeNewswire

Posted in Hormone Replacement Therapy | Comments Off on Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 – Industry Trends, Share … – GlobeNewswire

Menopause Demystified – UConn Today – University of Connecticut

Posted: May 27, 2024 at 2:49 am

Menopause transition is a natural part of a womens life that is overwhelmingly viewed as taboo and stigmatized as it is associated with aging. Many suffer because they are embarrassed to talk about it and think they have to suffer with the side effects. But this isnt true, there is help available.

During Womens Health month we spoke with Dr. Maryanne McDonnell, OB/GYN UConn Health to shed some light on this topic:

What are the stages of menopause? Menopause is divided into three basic stages: perimenopause, menopause, and post menopause. During this time, ovarian function first decreases and then finally stops the production of the hormones that stimulate the menstrual cycle; estrogen and progesterone.

Tell us about perimenopause, when does it start and what are the symptoms? Perimenopause is the time which your body makes the natural transition to menopause, when women start to have symptoms and will notice changes in their menstrual cycles. It starts at different ages; the majority of women start in their 40s and it can last anywhere from six-to-eight years on average.

Perimenopause symptoms may include menstrual changes, mood changes, changes in sexual desire, depression, trouble concentrating, headaches, night sweats, hot flashes, and trouble with sleep.

Most perimenopause symptoms are manageable. But if you need help managing symptoms, medications and other treatments are available. Perimenopause ends when youve had no period for a full year.

What is menopause and when does it happen? Menopause is a natural process that occurs when a womans ovaries stop releasing eggs and stops producing estrogen and progesterone. It marks the end of menstrual cycles and is diagnosed after you have gone one year without a menstrual period.

Menopause usually happens between the ages of 45 and 55, but the average age is 51. It can happen earlier or later in some women.

Some women experience no symptoms, while others may experience a combination of symptoms. These can be similar to perimenopause including hot flashes, night sweats, menstrual changes, vaginal dryness, sleep issues, mood changes, decreased libido, weight gain and difficulty concentrating. These symptoms can sometimes last for years after menopause.

A medical professional can help manage menopause symptoms and may prescribe hormone therapy in some cases.

What does the last stage, post menopause entail? Post menopause is the final stage of menopause and begins after a woman hasnt had a period for 12 months in a row. During post menopause, the body learns to function with lower hormone levels, and reproductive years are over. You will no longer have periods but some women do continue to experience symptoms of menopause.

What are the treatments for the symptoms of menopause? Menopause symptoms and treatment options vary, and treatments include hormonal therapy, non-hormonal medications, and lifestyle changes. The goal is to decrease symptoms to allow for better quality of life.

Hormone replacement therapy (HRT) estrogen can help by replacing a small amount of the hormone lost at the time of Menopause. It can help with hot flashes, night sweats, and other side effects of menopause. When a patient is taking estrogen and still has a uterus, progesterone is added to prevent uterine cancer.

Antidepressants- Low doses of some types of antidepressants may help relieve certain menopause symptoms like hot flashes, night sweats, mood changes.

Gabapentin a drug that is sometimes prescribed off-label to reduce hot flashes during menopause. Instead of affecting hormones, experts think it may act on the hypothalamus, the part of the brain that regulates body temperature.

Treatments for vaginal dryness Postmenopausal vaginal dryness can cause pain during intercourse and/or recurrent urinary tract infections. There are several treatment options for vaginal dryness. Some, such as vaginal moisturizers or lubricants, are available without a prescription. Others require a prescription; these include a vaginal estrogen cream, tablet, capsule, or ring; an oral medication called ospemifene; and a non-estrogen vaginal tablet called Prasterone.

Lifestyle changes include wearing layers of clothing, keeping your bedroom cool at night, taking a cool shower, use a fan, try to reduce your stress level, avoid, or reduce potential triggers, such as spicy food, caffeine, hot drinks, smoking and alcohol, exercise regularly, and lose weight if youre overweight.

Eating a nutritious diet rich in fruits, vegetables, and protein, among other nutrients, and getting regular physical activity may provide relief from menopause symptoms.

There are many supplements and products on the internet and social media that claim to help with symptoms of menopause. Do these really help? We must remember that supplements and many of the products sold online are not regulated by the FDA and have not been researched enough to confirm their effectiveness or safety. Patients should talk to their doctor before taking any type of supplement to determine it is safe. For those looking for natural ways to control symptoms, eating a nutritious diet rich in fruits, vegetables, and protein, among other nutrients, and getting regular physical activity may provide relief from menopause symptoms.

Dr. McDonnell recommends women suffering from symptoms that may or may not be linked to menopause speak to their health-care provider. You can get help with many of these symptoms you are experiencing and there is no need to do it alone.

Its important to know that there isnt a one-size-fits-all approach to symptoms or treatments, but working with your practitioner, you can find one that works for you.

The Womens Center at UConn Health offers OB/GYN services for women at every stage of their lives, providing access to award-winning doctors at a location thats close to home. Keeping our patients in mind, weve brought together general obstetrics and gynecology with specialized services and imaging, making appointments even more convenient.

Follow this link:
Menopause Demystified - UConn Today - University of Connecticut

Posted in Hormone Replacement Therapy | Comments Off on Menopause Demystified – UConn Today – University of Connecticut

Everything You’ve Ever Wanted to Know (But Were Scared to Ask) About Menopausal Hormone Therapy – AOL

Posted: May 27, 2024 at 2:49 am

If youve beenor are goingthrough menopause, you know it can be a doozy, between the acne, sleep difficulties, cognitive symptoms and lets not forget the hot flashes. One treatment for these symptoms is menopausal hormone therapy (MHT)which you might know by the name hormone replacement therapy, a treatment that replaces the hormones that your body isnt making enough of, thereby improving menopause symptoms like vaginal dryness and changes in mood. I checked in with Dr. Mary Jacobson, MD, to learn more about MHT, including benefits, risks and alternatives.

Dr. Mary Jacobson, MD, is the Chief Medical Officer of Hello Alpha, which aims to empower women to take control of their personal healthcare by providing patients with access to simple, everyday medical needs. Dr. Jacobson is an accomplished academic, board-certified obstetrician and gynecologist and minimally invasive surgeon with extensive experience in clinical care, medical education, hospital operations and research.

First things first, Dr. Jacobson tells me that hormone replacement therapy is an outdated phrase based on the mistaken belief that femalemenopausesignified a hormone deficiency. Instead, she says, The phrase, menopausalhormone therapy (MHT) or hormone therapy (HT),albeit nuanced, recognizesmenopauseas a natural stage of reproductive life.

Hormone therapy comes in many forms, including:

Per Dr. Jacobson, menopausal hormone therapy treats:

What Signals the End of Menopause? An OB/GYN on What to Expect at Every Stage

izusek/getty images

Dr. Jacobson tells me that MHT is FDA-approved for:

Moderate to severe VMS

Prevention of osteoporosis in postmenopausal women

Treatment of low estrogen levels due to hypogonadism (when your body does not produce enough sex hormones), removal of both ovaries, or primary ovarian insufficiency

Treatment of moderate to severe vulvovaginal symptoms

The risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation and whether a progestin is used, Dr. Jacobson explains. Risks of systemic estrogen therapy alone and combination estrogen and progestin include increased risk for venous thromboembolism and gallbladder disease. Additionally, she says, the combination estrogen and progestin carries a rare but increased risk for stroke and breast cancer. Patients with a uterus who take estrogen without an adequate amount of progestin are at increased risk of endometrial hyperplasia and endometrial cancer.

While MHT is appropriate for many symptomatic women, Dr. Jacobson says that there are some contraindications that would rule out hormone therapy as a treatment for menopause symptoms. These include a history of an estrogen-sensitive cancer (like breast cancer), coronary heart disease, heart attack, stroke and venous thromboembolism or inherited high risk of thromboembolic (blood clotting disease).

If you have one of these contraindications but are still looking for relief from menopause symptoms, dont fret; Dr. Jacobson tells me that there are a number of other medications that can help with symptoms, including the antidepressantsparoxetine (Brisdelle) and Venlafaxine (off-label), which provide mild to moderate improvements in vasomotor symptoms. Also, Gabapentin is associated with improvements in the frequency and severity of vasomotor symptoms. Fezolinetant (VEOZAH) is a novel, non-hormonal medication which treats moderate-severe vasomotor symptoms. Fezolinetant modulates neuronal activity in the thermoregulatory center of the hypothalamus in the brain.

Additionally, Dr. Jacobson says folks can try the below non-prescription based methods to manage their symptoms.

For VMS:

For Vaginal Symptoms:

Over the counter vaginal lubricants (e.g., Astroglide, OMy, K-Y Brand, Liquid Silk, Yes!, Pjur, Pink, Wet Platinum)

Menopausal hormone therapy is one of a number of treatmentsin addition to lifestylechanges, supplements, integrative therapies and prescription medicationsthat can ease vasomotor, vaginal and mood symptoms associated with menopause. While its helpful to read up on your options, only you and your doctor can determine what course of action is right for you.

10 Unusual and Lesser-Known Menopause Symptoms Every Woman Should Know About

Original post:
Everything You've Ever Wanted to Know (But Were Scared to Ask) About Menopausal Hormone Therapy - AOL

Posted in Hormone Replacement Therapy | Comments Off on Everything You’ve Ever Wanted to Know (But Were Scared to Ask) About Menopausal Hormone Therapy – AOL

Tracking the cellular and genetic roots of neuropsychiatric disease – Yale News

Posted: May 27, 2024 at 2:49 am

A new analysis has revealed detailed information about genetic variation in brain cells that could open new avenues for the targeted treatment of diseases such as schizophrenia and Alzheimers disease.

The findings, reported May 23 in Science, were the result of a multi-institutional collaboration known as PsychENCODE, founded in 2015 by the National Institutes of Health, which seeks new understandings of genomic influences on neuropsychiatric disease. The study was published alongside related studies in Science, Science Advances, and Science Translational Medicine.

Previous research has established a strong link between a persons genetics and their likelihood of developing neuropsychiatric disease, saysMark Gerstein, the Albert L. Williams Professor of Biomedical Informatics at Yale School of Medicine and senior author of the new study.

The correlations between genetics and your susceptibility to disease are much higher for brain diseases than for cancer or heart disease, said Gerstein. If your parents have schizophrenia, youre much more likely to get it than you are to get heart disease if your parents have the disease. There is a very large heritability for these brain-related conditions.

Whats less clear, however, is how this genetic variation leads to disease.

We want to understand the mechanism, said Gerstein. What is that gene variantdoingin the brain?

For the new study, researchers set out to better understand the genetic variation across individual cell types in the brain. To do so, they performed several types of single-cell experiments on more than 2.8 million cells taken from the brains of 388 people, including healthy individuals and others with schizophrenia, bipolar disorder, autism spectrum disorder, post-traumatic stress disorder, and Alzheimers disease.

From that pool of cells, the researchers identified 28 different cell types. Then they examined gene expression and regulation within those cell types.

In one analysis, the researchers were able to link gene expression to variants in upstream regulatory regions, bits of genetic code situated before the gene in question that can increase or decrease the genes expression.

Thats useful because if you have a variant of interest, you can now link it to a gene, said Gerstein. And thats really powerful because it helps you interpret the variants. It helps you understand what effect theyre having in the brain. And because we looked across cell types, our data also allow you to connect that variant to an individual cell type of action.

The researchers also assessed how particular genes, such as those associated with neurotransmitters, varied across individuals and cell types, finding variability was usually higher across cell types than across individuals. This pattern was even stronger for genes that code for proteins targeted for drug treatment.

And thats generally good for a drug, Gerstein said. It means that those drugs are homing in on particular cell types and not affecting your whole brain or body. It also means those drugs are more likely to be unaffected by genetic variants and work in many people.

Using the data generated by the analysis, the researchers were able to map out within-cell type genetic regulatory networks and between-cell communication networks, and then plug those networks into a machine learning model. Then, using an individuals genetic information, the model could predict whether they had a brain disease.

Because these networks were hard coded in the model, when the model made a prediction we could see which parts of the network contributed to it, said Gerstein. So we could identify which genes and cell types were important for that prediction. And that can suggest candidate drug targets.

In one example, the model predicted an individual with a particular genetic variant might have bipolar disorder, and the researchers could see that prediction was based on two genes in three cell types. In another, the researchers identified six genes in six cell types that contributed to a schizophrenia prediction.

The model also worked in the opposite direction. The researchers could introduce a genetic perturbation and see how that might affect the network and an individuals health. This, Gerstein says, is useful for drug design or previewing how well drugs or drug combinations might fare as treatments.

Together, the findings could help facilitate precision-medicine approaches for neuropsychiatric disease, said the researchers.

To further this work, the consortium hasmade its results and model availableto other researchers.

Our vision is that researchers interested in a particular gene or variant can use our resources to better understand what its doing in the brain or to perhaps identify new candidate drug targets to investigate more, said Gerstein.

See the original post here:
Tracking the cellular and genetic roots of neuropsychiatric disease - Yale News

Posted in Cell Medicine | Comments Off on Tracking the cellular and genetic roots of neuropsychiatric disease – Yale News

FDA grants CAR T-cell therapy Descartes-08 its RMAT designation – Myasthenia Gravis News

Posted: May 27, 2024 at 2:49 am

Cartesian Therapeutics investigational cell therapy Descartes-08 has been granted regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of myasthenia gravis (MG).

RMAT status is intended for experimental regenerative medicines to treat, modify, reverse, or cure a serious or life-threatening disease and which have shown preliminary clinical evidence of being able to address an unmet need for treating that disease.

Developers of RMAT-designated treatments receive all the incentives of fast track and breakthrough therapy designations, including early and intensive interactions with the FDA that can help hasten treatment development.

Descartes-08 has also been granted orphan drug designation by the FDA for MG, another status intended to speed the therapys development by offering regulatory support and financial incentives.

Receipt of RMAT designation underscores our belief that Descartes-08 could serve as a meaningful addition to the MG treatment landscape, Carsten Brunn, PhD, president and CEO of Cartesian, said in a company press release.

We look forward to working closely with the FDA to efficiently advance the development of Descartes-08 for this underserved population, Brunn added.

Meanwhile, Descartes-08 is being tested in MG patients in a Phase 2b clinical trial, called MG-001 (NCT04146051). Cartesian remains on track to announce top-line results from the study by mid-year.

MG, an autoimmune disease, is caused by self-reactive antibodies that attack healthy proteins residing at the site of communication between nerve and muscle cells. These antibodies are produced by certain types of immune B-cells.

Descartes-08 is designed to deplete the levels of these B-cells, thereby lowering the production of disease-driving antibodies and easing MG symptoms.

Immune T-cells have the means to kill off these B-cells, but they dont naturally know they should target them. With Descartes-08, T-cells are removed from a patients body and engineered in the lab to be equipped with a chimeric antigen receptor, or CAR, that specifically binds to a protein found on immune B-cells, called BCMA. When the modified T-cells are infused back into the patient, they are now equipped to specifically bind and destroy the harmful B-cells.

While the concept of CAR T-cell therapy for treating autoimmune diseases isnt new, Descartes-08 takes a unique approach to help avoid toxicity-related safety issues that are common with this type of therapy.

With most CAR T-cell therapies, the CAR is introduced by providing T-cells with DNA that encodes its production. While having the advantage of being a one-time treatment, this also requires that patients undergo chemotherapy to kill off existing immune cells before the treatment, leading to toxicity-related side effects.

Instead of delivering DNA, Descartes-08 delivers RNA, an intermediate molecule thats produced when converting the information in DNA to a working protein. While this RNA-based version requires repeat dosing, it also avoids the need for chemotherapy and is thought to have a better safety profile. That also means it can be administered as an outpatient procedure without hospital admission.

The MG-001 trial included Phase 1b, Phase 2a, and Phase 2b parts, all involving adults with generalized MG (gMG). After an initial Phase 1b dose-finding portion, 11 gMG patients were enrolled in the Phase 2a study. There, they were assigned to receive six into-the-vein infusions of Descartes-08 in various dosing schedules.

Across both the Phase 1b and Phase 2a parts, the treatment was well tolerated and not associated with side effects common with DNA-based CAR T-cell therapies, including neurotoxicity and cytokine release syndrome, both of which are serious types of immune responses.

Evidence of clinically meaningful improvements in measures of MG disease severity were observed among Phase 2a participants that persisted for months after the six-week treatment period ended in most patients. Levels of disease-driving antibodies in the bloodstream were also reduced.

In the ongoing Phase 2b study, up to 30 adults with gMG will be randomly assigned to receive six weekly doses of Descartes-08 or a placebo. The groups will then be switched, with those initially given Descartes-08 receiving a placebo and vice versa.

The main goal of this part of the trial is to compare the effects of Descartes-08 versus a placebo on a standard measure of patient-reported disease severity.

Go here to read the rest:
FDA grants CAR T-cell therapy Descartes-08 its RMAT designation - Myasthenia Gravis News

Posted in Cell Medicine | Comments Off on FDA grants CAR T-cell therapy Descartes-08 its RMAT designation – Myasthenia Gravis News

May: academy-medical-sciences | News and features – University of Bristol

Posted: May 27, 2024 at 2:49 am

Two Bristol academics, Professors Eugenia Piddini and Gene Feder OBE, have been elected to the Academy of Medical Sciences respected and influential Fellowship. They join 58 exceptional biomedical and health scientists selected for their exceptional contributions to the advancement of medical science.

The new Fellows, announced on Tuesday 21 May, have been recognised for their remarkable contributions to advancing biomedical and health sciences, groundbreaking research discoveries and translating developments into benefits for patients and wider society.

Awardees join an esteemed Fellowship of over 1,400 researchers who are at the heart of the Academy's work, which includes nurturing the next generation of researchers and shaping research and health policy in the UK and worldwide. The expertise of Fellows elected this year spans a wide range of clinical and non-clinical disciplines, from midwifery to cancer stem cell biology.

Eugenia Piddini, Professor of Cell Biology in the School of Cellular and Molecular Medicine, is conducting innovative work to identify cell competition-based strategies to gain control over tissue colonisation, its impact in tissue colonisation in regenerative medicine and to prevent tumour expansion in cancer.

A cell and developmental biologist,Eugenia is known for her seminal work in the field of cell competition the mechanism of tissue quality control that removes damaged cells from tissues. Eugenias discoveries have helped widen the scope of cell competition in terms of physiological relevance and potential therapeutic impact. Recently, Eugenias group demonstrated that cell competition acts in adult tissues. There it can potentially slow down the onset of disease/ageing by eliminating damaged cells.

Eugenias team has also shown that tumour cells kill surrounding normal cells via cell competition to free space for their own growth. Their work has identified many mechanisms and signals that cells use to compete. By explaining the mechanisms that cells use to compete the Piddini group aims to identify cell competition-based strategies to gain control over tissue colonisation.

In recognition of her work Eugenia, who is also School Research Director, was awarded the British Society for Cell Biology Hooke Medal in 2019 and in 2023, was elected as a Member of the European Molecular Biology Organisation.

Gene Feder, is a GP and Professor of Primary Care at Bristols Centre for Academic Primary Care, Bristol Medical School and Director of VISION, a UK Prevention Research Partnership (UKPRP) consortium.

Professor Feder leads ground-breaking national and international research on domestic violence and abuse (DVA) from epidemiology to health care response. He is the architect of IRIS, a national DVA programme for general practice, and co-founded IRISi, a social enterprise implementing IRIS nationally. He has extended his research globally through EU and Medical Research Council grants, and co-leadership of HERA, a National Institute for Health and Care Research (NIHR) Global Health Group in collaboration with researchers in Brazil, Nepal Sri Lanka, and the occupied Palestinian territories (oPT).

Committed to developing and evaluating effective and compassionate health care, Professor Feder has championed the use of randomised controlled trials to test improvements in general practice care of patients with heart and respiratory conditions, and robust methods to develop and implement clinical guidelines that make a difference to patients. He extended epidemiological, trial and meta-analytic methods to research on gender-based violence, combining quantitative and qualitive data to evaluate interventions, collaborating with statisticians, epidemiologists, economists, and social scientists. He has chaired four NICE guidelines and the World Health Organisation (WHO) intimate partner and sexual violence guideline development group.

In 2012, he co-founded the Foundation for Family Medicine in Palestine, which aims to support universal health coverage throughout the occupied Palestinian Territories based on effective, efficient and high-quality primary care. In 2016, Professor Feder was awarded an OBE for services to health care and survivors of domestic violence. In 2022, Gene was appointed Director of VISION, a five-year UKPRP inter-disciplinary consortium researching the intersection of violence and health to reduce and mitigate the effects of violence through better measurement and analysis of health care, police, criminal justice, and voluntary sector data. He is an expert advisor to UK Government and WHO.

Professor Andrew Morris PMedSci, President of the Academy of Medical Sciences, said: It is an honour to welcome these brilliant minds to our Fellowship. Our new Fellows lead pioneering work in biomedical research and are driving remarkable improvements in healthcare. We look forward to working with them, and learning from them, in our quest to foster an open and progressive research environment that improves the health of people everywhere through excellence in medical science.

This year's cohort marks a significant milestone in the Academy's efforts to promote equality, diversity and inclusion (EDI) within its Fellowship election. Among the new Fellows, 41 per cent are women, the highest percentage ever elected. Additionally, Black, Asian and minority ethnic representation is 29 per cent, an 11 per cent increase from the previous year. The new Fellows hold positions at institutions across the UK, including in Edinburgh, Birmingham, Liverpool, Manchester, Sheffield, Nottingham and York.

Professor Morris added: It is also welcoming to note that this year's cohort is our most diverse yet, in terms of gender, ethnicity and geography. While this progress is encouraging, we recognise that there is still much work to be done to truly diversify our Fellowship. We remain committed to our EDI goals and will continue to take meaningful steps to ensure our Fellowship reflects the rich diversity of the society we serve."

The new Fellows will be formally admitted to the Academy at a ceremony on Wednesday 18 September 2024.

The Academy of Medical Sciences is the independent, expert body representing the diversity of medical science in the UK. Its mission is to advance biomedical and health research and its translation into benefits for society. The Academy's elected Fellows are the most influential scientists in the UK and worldwide, drawn from the NHS, academia, industry and the public service.

About the Academy of Medical SciencesThe Academy of Medical Sciences is the independent, expert voice of biomedical and health research in the UK. Our Fellowship comprises the most influential scientists in the UK and worldwide, drawn from the NHS, academia, industry, and the public service. Our mission is to improve the health of people everywhere by creating an open and progressive research sector. We do this by working with patients and the public to influence policy and biomedical practice, strengthening UK biomedical and health research, supporting the next generation of researchers through funding and career development opportunities, and working with partners globally.

Read the rest here:
May: academy-medical-sciences | News and features - University of Bristol

Posted in Cell Medicine | Comments Off on May: academy-medical-sciences | News and features – University of Bristol

Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine’s Potential – Intelligent Living

Posted: May 27, 2024 at 2:49 am

We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalised ads. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Visit link:
Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine's Potential - Intelligent Living

Posted in Cell Medicine | Comments Off on Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine’s Potential – Intelligent Living

Stem Cell Therapy Market Size, Top Companies, Share, Growth And Forecast 2033 | CAGR 16.2% – openPR

Posted: May 27, 2024 at 2:48 am

Stem Cell Therapy Market

Read More: https://www.globenewswire.com/en/news-release/2023/11/17/2782506/0/en/Global-Stem-Cell-Therapy-Market-to-Reach-USD-928-6-Million-by-2031-Says-Allied-Market-Research.html

Stem Cell Therapy Market Statistics: The global Stem Cell Therapy market size is estimated to reach $928.6 million by 2031, growing at a CAGR of 16.2% from 2022 to 2031.

Stem Cell Therapy Market Growth Drivers:

Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions, has created a demand for innovative treatment options. Stem cell therapy offers potential solutions by promoting tissue regeneration and repair.

Advancements in Stem Cell Research: Continuous advancements in stem cell research, including the discovery of new cell sources, improved culturing techniques, and better understanding of stem cell behavior, have expanded the therapeutic applications of stem cell therapy. These advancements are driving the development of more effective and targeted treatment approaches.

Growing Aging Population: The global aging population is increasing, leading to a higher prevalence of age-related diseases and conditions. Stem cell therapy holds promise for addressing age-related degenerative disorders, such as osteoarthritis, Alzheimer's disease, and macular degeneration, by stimulating tissue repair and regeneration.

Favorable Regulatory Environment: Many countries are adopting supportive regulatory frameworks for stem cell therapy, which facilitate research, development, and commercialization of stem cell-based treatments. These regulations provide a conducive environment for companies and researchers to invest in stem cell therapy development.

Increasing Investments and Funding: There has been a surge in investments and funding for stem cell research and development from government bodies, private organizations, and venture capitalists. This financial support has accelerated the pace of research and clinical trials, leading to advancements in stem cell therapies.

Technological Advancements: Technological advancements, such as genetic engineering, tissue engineering, and 3D printing, have expanded the possibilities for stem cell therapy. These technologies enhance the precision, efficiency, and safety of stem cell-based treatments, opening new avenues for therapeutic applications.

Click To Get Sample Copy: https://www.alliedmarketresearch.com/request-sample/11317

The segments and sub-section of Stem Cell Therapy market is shown below:

By Cell Source: Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells, Other

By Application: Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Other

By Type: Allogeneic Transplants, Autologous Transplants

Some of the key players involved in the Market are: Allele Biotechnology and Pharmaceuticals, Astellas Pharma, Fujifilm Holding, Mesoblast, Novadip Biosciences, NuVasive, Orthofix, Smith & Nephew, Takeda Pharmaceutical, U.S. Stem Cell.

Important years considered in the Stem Cell Therapy study: Historical year - 2018-2022; Base year - 2022; Forecast period** - 2022 to 2032 [** unless otherwise stated]

If opting for the Global version of Stem Cell Therapy Market; then below country analysis would be included: - North America (USA, Canada and Mexico) - Europe (Germany, France, the United Kingdom, Netherlands, Italy, Nordic Nations, Spain, Switzerland and Rest of Europe) - Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India, Southeast Asia and Rest of APAC) - South America (Brazil, Argentina, Chile, Colombia, Rest of countries etc.) - Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Turkey, Nigeria, South Africa, Rest of MEA)

Key Questions Answered with this Study: 1) What makes Stem Cell Therapy Market feasible for long term investment? 2) How influencing factors driving the demand of Stem Cell Therapy in next few years? 3) Territory that may see steep rise in CAGR & Y-O-Y growth? 4) What geographic region would have better demand for product/services? 5) What opportunity emerging territory would offer to established and new entrants in Stem Cell Therapy market? 6) What strategies of big players help them acquire share in mature market? 7) Know value chain areas where players can create value? 8) What is the impact analysis of various factors in the Global Stem Cell Therapy market growth? 9) Risk side analysis connected with service providers?

Introduction about Stem Cell Therapy Market Stem Cell Therapy Market Size (Sales) Market Share by Type (Product Category) Stem Cell Therapy Market by Application/End Users Stem Cell Therapy Sales (Volume) and Market Share Comparison by Applications Global Stem Cell Therapy Sales and Growth Rate (2022-2032) Stem Cell Therapy Competition by Players/Suppliers, Region, Type, and Application Stem Cell Therapy (Volume, Value, and Sales Price) table defined for each geographic region defined. Stem Cell Therapy Players/Suppliers Profiles and Sales Data Key Raw Materials Analysis & Price Trends Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis ..and view more in complete table of Contents

Procure Complete Report@ https://www.alliedmarketresearch.com/checkout-final/139f33c6ac2962c73b01594c0c9673b5

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Contact Us: David Correa Portland, OR, United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com

About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.

Originally posted here:
Stem Cell Therapy Market Size, Top Companies, Share, Growth And Forecast 2033 | CAGR 16.2% - openPR

Posted in Stem Cell Treatments | Comments Off on Stem Cell Therapy Market Size, Top Companies, Share, Growth And Forecast 2033 | CAGR 16.2% – openPR

Study suggests approach for treating rare disorder – National Institutes of Health (NIH) (.gov)

Posted: May 27, 2024 at 2:48 am

At a Glance

Research into rare diseases and disorders is hampered by the limited number of people available to participate in studies. Many rare diseases and disorders also lack animal models that can help scientists perform early testing of new treatments.

One such rare disorder is Timothy syndrome. Problems with a single gene, called CACNA1C, cause this condition. CACNA1C codes for structures in cells called calcium channels. These help control signals throughout the brain and body. People with Timothy syndrome live with a range of severe symptoms including autism, epilepsy, and interruptions in the hearts normal electrical activity.

After the CACNA1C gene is transcribed into RNA, the RNA can be spliced in different ways to make different versions of the protein. Normally, splicing changes cause one version of the protein to be produced during development, and then another later on. In Timothy syndrome, the first version continues to be produced instead. As a result, calcium channels remain overactive, causing abnormal electrical activity in the bodys cells.

Researchers have been developing compounds called antisense oligonucleotides, or ASOs, to treat some rare genetic disorders. ASOs bind to small portions of RNA to affect how the RNA is processed. In a new study funded in part by NIH, a research team led by Dr. Sergiu Paca from Stanford University tested whether ASOs could block the changes in RNA that cause Timothy syndrome.

The team firstgrew 3D human brain tissue structures called organoids from stem cells donated by people with Timothy syndrome. The study was published on April 25, 2024, in Nature.

The researchers developed several ASOs that, in organoids grown to mimic the brains cerebral cortex, reduced the abnormal RNA splicing. Adding the two most promising ASOs to organoids derived from people with Timothy syndrome restored the functioning of calcium channels to normal levels.

To see whether the treatment could restore normal cell movements during brain development, the team created more complex structures called assembloids. These were made from different organoids fused together to mimic the human forebrain. Treating these assembloids with ASOs restored the normal movement of brain cells during development.

Timothy syndrome manifests during early development. To test how the ASOs might work in the developing brain, the researchers transplanted the human-derived organoids into the brains of newly born rats. The organoids integrated successfully into the growing brain tissue. When the researchers injected the rats with one of the ASOs, production of the abnormally spliced RNA was reduced. Calcium channels in the resulting cells worked more normally, and the cells looked normal under the microscope.

Our study showed that we can correct cellular deficits associated with Timothy syndrome, Paca says. We are now actively working towards translating these findings into the clinic, bringing hope that one day we may have an effective treatment for this devastating neurodevelopmental disorder.

Notably, the approach used in this study has potential for studying new treatments for other rare genetic disorders as well. Many challenges, however, still need to be solved before this technology could be used in the clinic.

References:Antisense oligonucleotide therapeutic approach forTimothysyndrome. Chen X, Birey F, Li MY, Revah O, Levy R, Thete MV, Reis N, Kaganovsky K, Onesto M, Sakai N, Hudacova Z, Hao J, Meng X, Nishino S, Huguenard J, Paca SP. Nature. 2024 Apr;628(8009):818-825. doi: 10.1038/s41586-024-07310-6. Epub 2024 Apr 24. PMID:38658687.

Funding:NIHs National Institute of Mental Health (NIMH); Stanford University; Autism Speaks, Inc.; Kwan Funds; Senkut Funds; Coates Foundation; Ludwig Family Foundation; Alfred E. Mann Foundation; New York Stem Cell Foundation; Chan Zuckerberg Initiative.

Read the original:
Study suggests approach for treating rare disorder - National Institutes of Health (NIH) (.gov)

Posted in Stem Cell Treatments | Comments Off on Study suggests approach for treating rare disorder – National Institutes of Health (NIH) (.gov)

Page 67«..1020..66676869..8090..»